By Dean Seal
Shares of Iterum Therapeutics surged after federal regulators approved the use of its urinary tract infection treatment Orlynvah.
The stock was up 64% at $1.92 around noon ET, closer to where it started the year.
The clinical-stage pharmaceutical company said Friday that the Food and Drug Administration has approved its new drug application for Orlynvah as a treatment for uncomplicated urinary tract infections caused by certain microorganisms in adult women with limited or no alternative oral antibacterial treatment options.
This is the first approved indication for Orlynvah and Iterum's first FDA-approved product.
Chief Executive Corey Fishman said that with the approval, Iterum will renew efforts to land a strategic transaction involving Orlynvah.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
October 25, 2024 12:04 ET (16:04 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.